Introduction
The Philadelphia chromosome (Ph + ) is characterized by a reciprocal translocation t (9:22) , causing the c-abl proto-oncogene on chromosome 9 to fuse with the breakpoint cluster region (BCR) gene on chromosome 22 . This translocation is found in nearly all patients with chronic myelogenous leukemia (CML) and in about 20% of adult patients with acute lymphoblastic leukemia (ALL) carrying a poor prognosis. [1] [2] [3] [4] The product of the translocation is a bcr/abl fusion protein which forms a dimer and results in constitutive activation of abl. Depending upon the breakpoint in the bcr gene, several sized fusion proteins may be expressed, most commonly the p190 and p210 forms. 5, 6 In cell lines, expressing the p190 form of bcr/abl the fusion protein appears to inhibit apoptosis and induce expression of anti-apoptotic proteins of the Bcl-2 family. [6] [7] [8] [9] [10] [11] The mechanism by which the bcr/abl fusion protein induces leukemogenesis, however, still remains unclear.
In the present work, we utilize a mouse model in which the p190 form of bcr/abl is ubiquitously expressed under control of the methallothionein promoter. [12] [13] [14] [15] These mice are considered to be a good experimental model for human Ph + ALL, as they reproducibly develop malignancies limited to pre-B cell leukemia/lymphoma. p190 bcr/abl is expressed in the mouse bone marrow both prenatally and postnatally 14 and pre-B cell B lineage cells normally undergo extensive apoptotic cell death as they develop in mouse bone marrow. [16] [17] [18] In particular, an early checkpoint at the pro-B/pre-B cell transition removes a high proportion (70%) of developing cells, many of which may have sustained genetic damage, especially during the process of V H gene recombination and would be potentially dysregulated if allowed to survive. 19, 20 To examine further the role of p190 bcr/abl in B cell oncogenesis and to determine whether the transgene may exert an anti-apoptotic effect during B lymphopoiesis in vivo, twocolor immunofluorescence labeling and flow cytometry have now been used to quantitate phenotypically defined precursor B cell populations and to measure their apoptotic rate in bone marrow of p190 bcr/abl transgenic mice over a wide age range.
Materials and methods

Transgenic mice
Mice transgenic for p190 bcr/abl fusion protein were the progeny of the p190 bcr/abl transgenic mouse line 623, [12] [13] [14] [15] originally established by Groffen and colleagues. Briefly, one-cell fertilized eggs from C57BLxCBA (F1) matings were microinjected with a p190 bcr/abl construct driven by a metallothionein promoter. 12 The founder animal was the offspring of matings between C57BLxCBA (F1) animals. The original mouse 623 had two copies of the transgene and died at 198 days of age. 12 Transgenic progeny were produced by mating transgenic and normal C57BLxCBA (F1) mice. Animals of the transgenic line established from founder 623 develop and die exclusively of pre-B cell type lymphoblastic lymphoma/leukemia. 12, 21 Mice obtained from Dr J Groffen (Children's Hospital, Los Angeles, CA, USA) were bred in the McGill University Medical Sciences Animal Facility. Control mice used in the experiments were normal BL6xCBA (F1) mice purchased from Jackson Laboratory (Bar Harbor, ME, USA).
The work was performed on a total of 94 mice, consisting of 47 p190 bcr/abl transgenic mice and 47 control mice evaluated individually. Groups of three to seven transgenic mice and control mice were examined at each time point, as follows: 8 weeks, three mice; 12 weeks, five mice; 14 weeks, four mice, 16 weeks, four mice; 18 weeks, five mice; 20 weeks, four mice; 22 weeks, six mice; 26 weeks, six mice; 30 weeks, seven mice. At each time point, the controls were matched with transgenics by both age and sex. In the whole study, there were approximately equal numbers of male (24) and female (23) mice in both transgenic and control groups. Each sex was distributed throughout all time periods, except at 10 weeks when all mice were male.
Genotyping of the mice was performed using the standard Southern blot method. In brief, a one-inch piece of tail was cut from each mouse and placed in tail buffer, including protease K (Stratagene, San Diego, CA, USA). DNA was extracted using the phenol/chloroform method, followed by an ethanol wash. The pure DNA was overnight digested with two restriction enzymes, XhoI and HindIII (Gibco, Life Technologies, Grand Island, NY, USA). After a brief re-precipitation with ethanol, the samples were run on a 1% agarose gel at 30 V overnight. The gel was transferred to a hybond-N+ (Amersham, Illinois, IL, USA) Nylon Transfer Membrane using 25 n HCl and 4 m NaOH. The probe consisted of a 600 bp fragment (XhoI (X)/BglII (Bg)) of bcr exon (E)1. Labeling of the probe consisted of using the 32 P␣dCTP (Amersham) and the Stratagene Prime-It RMT Random Primer Labeling Kit (Stragagene). The membrane was probed overnight at 42°C and then washed and exposed to film at −80°C for 2-3 days.
Bone marrow cell suspension and short-term culture
Mice were killed by cervical dislocation and bone marrow cells were flushed out of all femoral shafts using minimum essential medium with l-glutamine (MEM; Life Technologies) supplemented with 10% (v/v) newborn calf serum (NCS; Life Technologies). After washing with NCS, nucleated cells were counted using an electronic particle counter (Coulter Corporation, Burlington, Ontario, Canada). Cell suspensions were adjusted to 40 × 10 6 cells/ml in MEM-NCS. Aliquots of cell suspensions (100 l) were either assayed immediately or incubated in MEM-NCS for 6 h at 37°C with 5% CO 2 , as described. 17 
Immunophenotypic staining of B lineage cells
For phenotypic study, bi-color immunolabeling was carried out, paired as B220: total and surface IgM:total . For apoptotic study, single-color immunolabeling was carried out before DNA labeling. To label cell surface B220 and IgM, bone marrow cell samples were incubated with either fluorescein isothiocyanate (FITC)-conjugated or R-phycoerythrin (PE)-conjugated anti-mouse B220 monoclonal antibody (mAb) (RA3-6B2; Pharmingen, San Diego, CA, USA) and either FITC-conjugated or PE-conjugated goat anti-mouse IgM ( heavy chain specific) (Southern Biotechnology, Birmingham, AL, USA), respectively (15 min, 4°C, in dark), as described. 17 To examine total expression, including both cytoplasmicchains (c) and the -chains of surface IgM molecules, bone marrow cells were fixed dropwise with ice-cold 70% ethanol (50 min, 4°C), washed extensively with PBS and incubated with FITC-conjugated chain-specific goat anti-mouse IgM (Southern Biotechnology) mAb for 1 h. 17 Samples stained with isotype-matched mAbs of irrelevant specificity were used as negative controls. To examine cell surface expression of pre-B cell receptor (pre-BCR), bone marrow cells were incubated with rat anti-mouse 5 mAb SL156 22 (kindly provided by Dr F Melchers, Basel Institute for Immunology, Basel, Switzerland), revealed by FITC-goat anti-rat IgG mAb (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA). MAb SL156 detects the 5 component of surrogate light chain as a complex with heavy chain on the surface of mouse pre-B cells. 22 Rat IgG (Pharmingen) was used in place of mAb SL156 to determine background fluorescence.
DNA content staining
After immunofluorescent phenotypic staining, cell samples were washed with NCS and Ca 2+ -and Mg 2+ -free phosphatebuffered saline (PBS; Life Technologies), ethanol-fixed, as above, and washed thoroughly with PBS. Samples were suspended in 50 g/ml Rnase (Boehringer Mannheim, Mannheim, Germany) and 50 g/ml propidium iodide (PI; Sigma Chemical, St Louis, MO, USA) in PBS and kept on ice in dark until analyzed, as described. 17 
Flow cytometric analysis of B cell phenotypes and apoptosis
After phenotypic and PI staining, single cell suspensions were analyzed using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA) equipped with a doublet discrimination module. FITC, PE and PI were excited with the 480 nm line of an argon laser, and emissions were detected at 550 and 650 nm, respectively. A minimum of 10 000 events was collected for each sample, gated on forward scatter vs side scatter to exclude debris and cell clumps. Data were acquired and analyzed using FACScan LYSYS II software (Becton Dickinson). Phenotypic populations were identified by positive staining of each marker. Large and small cells were identified by gating on forward scatter vs side scatter. Apoptotic cells were identified in the hypodiploid region of DNA content profiles, as described. 17 
Statistics
Statistical analysis was performed using Student's t-test. P Ͻ 0.05 was considered significant.
Results
p190 bcr/abl transgenic mice
Mice transgenic for a p190 bcr/abl construct 12 controlled by a metallothionein promoter develop lymphoblastic leukemia/ lymphoma of pre-B phenotype. [13] [14] [15] The p190 bcr/abl mice (line 623) 2 used in the present study died with overt leukemia/lymphoma, consistent with the previously published age-related mortality curve. 15 Rapid tumorigenesis occurred with a latent period of 6 weeks after birth, the mortality increasing steeply from 20% at 8 weeks to 50% at 10 weeks and 70% at 12 weeks of age. Thereafter, the mortality increased at a slower rate to 90% at 30 weeks, and, finally, over a further 30 week period, reached 96% at 60 weeks of age. Events taking place in the B cell lineage within the bone marrow were examined at intervals throughout the initial 4 week period of rapid tumorigenesis at 8-12 weeks of age, and a subsequent phase of continuing but slower tumor onset until 30 weeks of age. All mice were screened by blood leukocyte counts, microscopic examination of peripheral blood smears, bone marrow and spleen to exclude animals that had already developed leukemia/lymphoma. The study was restricted to clinically healthy mice.
Precursor B cell populations in bone marrow of p190 bcr/abl transgenic mice
The total number of nucleated cells recovered from the bone marrow showed age-related changes, differing between p190 bcr/abl transgenic mice and normal age-and strainmatched control mice ( Figure 1 ). In control bone marrow, the total cellularity fell initially from 8 to 10 weeks, but then showed no marked change throughout the rest of the experimental period. In contrast, the bone marrow cellularity in p190 bcr/abl transgenic mice was increased above normal levels and fluctuated widely with age, being particularly elevated at 8-10 weeks and 14-20 weeks (Figure 1 ). Recalculating these data according to sex, showed close correspondance between male and female curves both for transgenic and control groups. There was no appreciable sex-related difference in the fluctuating levels and time course of bone marrow cellularity in p190 bcr/abl transgenic mice (data not shown). The percentage of bone marrow cells expressing the B lineage-associated glycoprotein, B220 (Figure 2 ), was increased in p190 bcr/abl transgenic mice from 14 weeks onwards (Table 1) . When calculated as the absolute number of cells per femur, the B220 + B lineage cellularity followed a near-normal course at 8-12 weeks but subsequently exceeded control values throughout the rest of the study ( Figure 1 ). B220
+ cells were the major source of the increased total cellularity of p190 bcr/abl transgenic bone marrow. In addition, however, most of the increased cellularity at 8-10 weeks (5-6 × 10 6 cells per femur) and a fraction of the increase at 16-20 weeks (3.5-7.5 × 10 6 cells per femur) were due to unidentified B220-negative cells.
Figure 1
Number of total nucleated cells and B220 + B lineage cells in bone marrow of p190 bcr/abl transgenic mice and control mice at various ages from 8 weeks to 30 weeks. Mean ± s.d. derived from groups of three to seven mice (see text for details) (*P Ͻ 0.05; **P Ͻ 0.01).
Leukemia
To examine possible effects of p190 bcr/abl transgene expression during the process of B lymphopoiesis, double immunofluorescence labeling and flow cytometry have been used to define three successive stages of B cell differentiation, as shown in Figure 2 . [16] [17] [18] Pro-B cells express B220 in the absence of chains, a phenotype that consists predominently of B lineage cells plus a minor fraction of early progenitor cells with diverse potentials. 23, 24 Pre-B cells express c but not sIgM, and they include both large dividing pre-B cells and small postmitotic pre-B cells. B cells express surface chains in IgM molecules.
In control mice, B220 + cells declined in incidence from 8 weeks to 14 weeks of age (Table 1) and B cells at all stages of development decreased in absolute number (Figure 3 ), in accord with previous findings of an age-related decline in bone marrow lymphocyte production from early post-natal life to young adulthood. 25 In p190 bcr/abl transgenic mice, precursor B cell populations showed distinctive deviations from the normal pattern of development. During an initial phase at 8-12 weeks, the number of pro-B cells followed a normal course, while pre-B cells and B cells showed small increases in number ( Figure 3) . Thereafter, all three B lineage populations became increased in incidence at 14 weeks (Table 1 ) and expanded to 170-175% of normal absolute numbers ( Figure 3) . A peak of pro-B cell and large pre-B cell numbers at 14 weeks was followed by expansion of small pre-B cells at 18 weeks (Figures 3, 4) , while B cells were consistently increased in incidence (Table 1) 
Age-related perturbation of apoptosis among precursor B cells of p190 bcr/abl transgenic mice
It has been demonstrated previously that dissociated bone marrow cell suspensions in short-term culture undergo apoptosis at a linear rate, the apoptotic cells accumulating in intact form without being ingested by macrophages. 17 Double immunofluorescence labeling of DNA in conjunction with B lineage markers after 6 h in vitro incubation of bone marrow suspensions from p190 bcr/abl transgenic mice and control mice has revealed the incidence of hypodiploid cells, previously shown to be a reliable criterion of apoptosis among mouse bone marrow cells. 17 The short-term culture method has provided a sensitive assay by which to compare rates of spontaneous apoptosis between bone marrow samples from p190 bcr/abl transgenic mice and control mice at each age interval. Representative examples are illustrated in Figure 5 .
Apoptotic activity of B lineage cells changed substantially with age and differed markedly between p190 bcr/abl transgenic and control mice. In control mice, the overall apoptotic rate of B220 + cells was relatively constant from 10 weeks of age onwards, having fallen from a higher rate at 8 weeks ( Figure 6 ). In p190 bcr/abl transgenic mice, the B220 + cell population as a whole underwent apoptosis to a greater extent than controls at all ages from 10 weeks onwards ( Figure 5 ). However, dissection of successive stages of B cell development revealed striking differences in their age-related patterns of apoptotic activity (Figure 7) .
During normal B cell development in control mice, pro-B 
Figure 2
Stages of B lymphocyte development in normal mouse bone marrow, showing phenotypic markers used in the present study: B220 glycoprotein, intracytoplasmic chains, pre-B cell receptor (:sL), and surface IgM (sIgM) molecules. cells and pre-B cells showed contrasting apoptotic changes from 8 to 12 weeks of age ( Figure 7) . Pro-B cell apoptotic rates fell steeply from exceptionally high values at 8 weeks, while the apoptotic activity of pre-B cells increased sharply from exceptionally low values at 8 weeks, until both phenotypic cell compartments showed closely similar apoptotic frequencies from 12 weeks onwards ( Figure 7 ). The fraction of apoptotic cells among the B cell population remained constant from 10 weeks of age onwards, being half the level of apoptosis among pro-B cells and pre-B cells (Figure 7) .
Apoptosis of B lineage cells in p190 bcr/abl transgenic mice differed from normal age changes in a developmental stagespecific manner (Figure 7 ). Pro-B cells differed only slightly from normal apoptotic activity, except for transient increases at 14 weeks of age and at late intervals ( Figure 7) . In marked contrast, pre-B cell apoptotic rates were substantially depressed to only one third to one half normal values from 8 weeks to 14 weeks of age. Thereafter, pre-B cell apoptosis peaked above normal values at 16 weeks and at 22-26 weeks (Figure 7) . B cells, unlike the two preceding populations, showed elevated apoptotic activity from 10 weeks onwards, with particularly high values at 16 weeks and terminally at 26-30 weeks (Figure 7) . When calculated as the number of cells per femur, the pre-B cell population at 8-12 weeks was the only one to show a reduction in the absolute number of cells undergoing apoptosis per unit time. These cells subsequently increased to twice normal numbers in surviving mice at 16 weeks and 22 weeks of age. The absolute number of apoptotic B cells was approximately twice normal from 14 weeks to 22 weeks, increasing to four-fold normal numbers at 30 weeks of age. The most striking anomaly during the period of rapid tumorogenesis from 8 weeks to 14 weeks of age was thus an inhibition of the normal rapid increase in apoptotic rate among pre-B cells during this period (Figure 7 ).
Cell cycle status of B lineage cells in p190 bcr/abl transgenic mice
DNA content analysis of freshly prepared bone marrow suspensions ex vivo was performed at three representative ages, as shown in Table 2 . The proportion of B lineage cells in S/G2/M phases of cell cycle was slightly higher in p190 bcr/abl transgenic mice than in control mice. This finding, suggesting a somewhat shortened cell cycle, was most evident at 22 weeks of age.
Pre-BCR-expressing cells in bone marrow of p190 bcr/abl transgenic mice
During the phase of rapid leukemogenesis (8-12 weeks), pre-BCR-expressing cells detected by mAb SL156 in p190 bcr/abl transgenic mice often showed reduced rates of apoptosis and increased numbers (Table 3) , and they formed a higher proportion of the pre-B cell population (30%) than in agematched controls (17%). At later ages, the apoptotic rate among pre-BCR-expressing cells fell to reach similar levels in both p190 bcr/abl transgenic and control mice (Table 3) , and the number of pre-BCR + cells represented a similar proportion of the total pre-B cell population in each case (20-24%), consistent with previous reports.
18,22 At 6 weeks of age, before the onset of tumorigenesis, pre-BCR-expressing cells exhibited exceptionally low apoptotic rates in both p190 bcr/abl transgenic and control mice (Table 3) .
Discussion
B cell leukemogenesis is a multistep process that may be initiated during early stages of B cell development in the bone marrow. [26] [27] [28] Here, we show that a p190 bcr/abl transgene results in selective inhibition of apoptosis by pre-B cells in mouse bone marrow during early postnatal life, as a prelude to the development of pre-B leukemia/lymphoma. Many pre-B cells that have sustained genetic errors during their development and would normally be diverted into an apoptotic cell death pathway may thus be permitted to survive. This could constitute, for some cells, a critical step in oncogenesis.
B lymphopoiesis normally shows extensive apoptotic cell death at two quality control checkpoints. 17, 19, 20 The first, at the pro-B/pre-B transition, eliminates many cells that either have sustained DNA damage and genetic errors, including chromosomal translocations, while rearranging heavy chain gene segments or have undergone nonproductive rearrangements. The second checkpoint eliminates newly formed immature B cells expressing self-reactive IgM specificities or faulty light chain gene rearrangements. Unexpectedly, the present results in normal nontransgenic mice demonstrate that apoptotic activity among early precursor B cells is not constant with age but changes in a developmental stage-specific manner. In 8-week-old mice apoptotic activity is initially high among pro-B cells but low among pre-B cells. During the fol-
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Figure 4
Number of large pre-B cells (above) and small pre-B cells (below) in bone marrow of p190 bcr/abl transgenic mice and control mice of various ages. Mean ± s.d. derived from groups of three to seven mice (*P Ͻ 0.05; **P Ͻ 0.01). lowing 4 weeks, rapid inverse changes then bring pro-B and pre-B cells to a similar apoptotic rate from 12 weeks of age onwards. The first major phase of negative B cell selection thus appears to operate at different stages in B cell development with advancing age. Selection at 8 weeks occurs mainly at a very early stage among pro-B cells that would be undergoing chain gene rearrangement. Apoptosis of the many DNAdamaged cells at this stage is p53-mediated. 29 Having removed defective cells, the surviving fraction of pro-B cells may be expected to proceed through the subsequent pre-B cell stage with only minimal apoptotic loss. This is in accord with the present observations. After 8 weeks of age, while less selection occurs at the pro-B cell stage more cells are deleted as pre-B cells. Further studies are warranted to examine whether these temporal changes in the early apoptotic checkpoint may reflect changes in DNA damage or repair, p53 expression, proliferative activity, pre-B cell receptor expression, local growth factors, or other mechanisms. The present study appears to be the first report of age-related changes in apoptotic activity of precursor B cell populations during normal B cell development.
The effects induced in B lymphopoiesis by p190 bcr/abl transgene are also age-related. Although the transgene is expressed in bone marrow cells from fetal life onwards, 21 the oncogenic effects only become apparent after a latent period. The present data fall into two phases, a 4 week period of rapid tumorigenesis at 8-12 weeks of age, resulting in 70% mortality, and a subsequent 18 week period of much slower tumor onset causing mortality in a further 20% of mice. The early phase provides the most instructive observations since they represent 
Figure 6
Incidences of hypodiploid apoptotic B220 + B lineage cells in bone marrow cell suspensions from p190 bcr/abl transgenic mice and control mice of various ages after 6 h in vitro incubation. Mean ± s.d. derived from groups of three to seven mice (*P Ͻ 0.05; **P Ͻ 0.01).
Figure 7
Incidences of hypodiploid apoptotic B cells at various defined stages of development in bone marrow cell suspensions from p190 bcr/abl transgenic mice and control mice of various ages after 6 h in vitro incubation. Mean ± s.d. derived from groups of three to seven mice (*P Ͻ 0.05; **P Ͻ 0.01).
Table 2
Percentage of B lineage cells in S/G2/M phases of cell cycle in bone marrow of p190 bcr/abl transgenic mice and control mice at various ages Age B220 Pre-B cell apoptosis in p190 bcr/abl transgenic mice Q Yu et al 825 Table 3 Pre-BCR-expressing cells in bone marrow of p190 bcr/abl transgenic mice events occurring in a large fraction of the population of p190 bcr/abl transgenic mice, destined soon to develop leukemia/lymphoma. This provides an excellent model in which to study the evolution of disease with time. The results emphasize the need to relate disease mechanisms to the age of the individual. Observations based on a single age may be inadequate or misleading.
Although p190 bcr/abl in the present model is expressed ubiquitously, the resulting tumors are restricted to the B cell lineage and pre-B cell phenotype. These restrictions may be related to the lineage-specific process of gene rearrangement, with its attendant risk of genetic aberration, and the fact that a major apoptotic quality control checkpoint is located at or near the pro-B/pre-B stage of B cell development. The key finding in the bone marrow during the preleukemic phase is a marked suppression of apoptosis exclusively effecting the pre-B cell compartment, the developmental stage from which leukemia/lymphoma emerges. Conversely, abl gene deficiency is associated with B cell depletion 30 and a substantial increase in pre-B cell apoptosis (Lu, Rottapel, Wu and Osmond, unpublished) . Evidence indicates that anti-apoptotic effects of abl tyrosine kinase in a variety of other cell systems are mediated through changes in expression of bcl-2 family proteins. [7] [8] [9] [10] [11] 31, 32 This is also the likely mechanism by which p190 bcr/abl suppresses apoptosis in the B cell lineage. Other factors that help to determine the survival fraction of precursor B cells in mouse bone marrow by altering the ratio of antiapoptotic and pro-apoptotic bcl-2 family proteins include interleukin-7 and recombinase-activating genes. 33 Overexpression of bcl-2 in transgenic mice promotes precursor B cell survival. 34 Why the effect of p190 bcr/abl is restricted to pre-B cells requires further study. An analogous effect can be produced by Blk, another Src family-related tyrosine kinase. Expression of a Blk transgene in the B cell lineage in mice produces after short latency a high incidence of lymphomas with early B progenitor phenotype. 35 As in the present p190 bcr/abl transgenic model, the preferential transformation of these particular cells, despite the transgene being expressed throughout all identified stages of the B lineage in bone marrow, suggests an intrinsic sensitivity of the target stage to the action of the overexpressed kinase. Possibly, these ubiquitously expressed kinases require the co-operating effect of other as yet unidentified molecules that are themselves developmentally regulated and become expressed at the pre-B cell stage.
The present findings provide evidence that the salient effect of the p190 bcr/abl transgene in predisposing to leukemia/lymphoma is the suppression of pre-B cell apoptosis. The pro-B cell compartment in p190
bcr/abl transgenic mice shows normal age-related changes in size and apoptotic bcr/abl transgenic mice, however, do so at times when the pre-B cell population is only slightly larger than normal and there is evidence of only a small increase in the rate of cell proliferation. Hence, in contrast with some other animal models, including IL-7 transgenic and E-myc transgenic mice, 33, 36, 37 proliferative hyperplasia of precursor B cells is not a major feature of the preleukemic state in p190 bcr/abl transgenic mice. Instead, the findings suggest a causative link between suppression of apoptosis and the process of oncogenesis. It is proposed that p190 bcr/abl -induced inhibition of apoptosis allows the survival of many pre-B cells with genetic errors resulting from mistakes in V H gene rearrangement. Some of these genetic aberrations, together with the continuing activity of p190 bcr/abl kinases and other co-operating oncogenes, may block further differentiation and immortalize the cell in a proliferative state. Secondary genetic and karyotypic changes may occur with time during tumor progression after dissemination of the malignant clone via the blood stream. 13, 26, 38 Successful pairing of newly synthesized heavy chains with surrogate light chains early in the pre-B cell stage in mouse bone marrow results in the transient surface expression of pre-BCR, a molecule that appears to play a critical role in determining the ability of the cell to survive and proliferate. 19, 39 Similar to the pre-B cell population as a whole, the pre-BCR-expressing cells in p190 bcr/abl transgenic mice show some inhibition of apoptosis and expansion in numbers during the phase of rapid tumorigenesis. These findings suggest that the anti-apoptotic effect of the p190 bcr/abl transgene is manifested from the beginning of the pre-B cell stage. Whether pre-BCR, itself, may be directly implicated in mediating the p190 bcr/abl transgene effect remains to be determined. The older p190 bcr/abl transgenic mice examined in the present study during the phase of late onset disease represent an increasingly select and diminishing fraction of the starting population. The long latent period exhibited by these mice could be ascribed either to chance, reflecting a stochastic generation of genetic aberrations, or to the development of antitumor mechanisms. During much of the late phase, pre-B cell apoptosis is no longer inhibited. Conditions appear to evolve in time either to downregulate or to neutralize the anti-apoptotic effects of the p190 bcr/abl transgene. The phase is marked instead by an abrupt expansion of the B cell lineage, favoring the more mature phenotypes with advancing age. The increased numbers of B lineage cells are associated with evi-dence of moderately increased rapidity of cell cycling, especially at the pro-B cell stage. The mechanisms responsible for these changes are unknown. Proliferation of precursor B cells is critically influenced by molecular interactions with bone marrow stromal cells and short-range growth factors. 40, 41 Possibly, some of the late effects observed in p190 bcr/abl transgenic mice may be due to microenvironmental influences reflecting the ability of the chimeric bcr/abl gene to modify cell adhesion and actin structure. 6, 42 In addition, it remains to be determined to what extent the large increase in number of s + B cells observed in the oldest p190 bcr/abl transgenic mice represent either newly formed B cells retained in the bone marrow or mature B cells re-entering the bone marrow from the peripheral B cell pool.
The effects of the p190 bcr/abl transgene in mouse bone marrow are not restricted exclusively to the B cell lineage. Certain B220-negative cells of unknown phenotype and developmental potential are also increased in number both during the initial rapidly tumorigenic phase and at 16-20 weeks of age. Further studies may be warranted to examine whether p190 bcr/abl promotes the survival of progenitor cells committed to non-B cell lineages.
The finding that p190 bcr/abl exerts a selective anti-apoptotic effect on early B cell development during a preleukemic phase in mouse bone marrow raises the possibility that the naturally occurring Ph + chromosome, t(9:22), associated with p190
bcr/abl product similarly may initiate ALL in human patients by inhibiting B cell apoptosis. As in the p190 bcr/abl transgenic mouse, suppression of normal quality control mechanisms could permit B lineage cells harboring faulty DNA recombination events to survive as potentially neoplastic cells. To examine this hypothesis further it could thus be of interest to assay the apoptotic behavior of precursor B cell populations during the evolution of ALL in Ph + patients.
